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ancreatic islets are highly vascularized, which is
important in their ability to quickly secrete insu-
lin in response to changes in blood glucose.
Although pancreatic islets comprise only 1–2% of
pancreatic mass, they receive 5–10% of pancreatic blood
ﬂow. Blood vessels within pancreatic islets are of a greater
density than those in surrounding exocrine tissue and are
lined with fenestrated endothelial cells. These specialized
features are responsible for the greater partial pressure of
oxygen in islets compared with acinar tissue and other
organs, which is likely important for normal islet cell
function. Islet production of angiogenic factors such as
vascular endothelial growth factor-A (VEGF-A) and angio-
poietin-1 is critical for creating this highly vascularized
state (1,2). During embryonic development, reciprocal
endothelial-endocrine cell signaling and the formation of
functional blood vessels appear to instruct pancreatic
differentiation and morphogenesis (3–5). Development of
the islet vasculature is coordinated with islet formation,
but blood ﬂow to endocrine cells precedes their ﬁnal
assembly into a mature islet (2).
Pancreatic islet isolation severs the connections be-
tween the islet vasculature and the systemic circulation. In
contrast with whole-organ transplantation, where organ
perfusion is quickly reestablished by reconnection of
arterial and venous vessels, the reestablishment of blood
ﬂow to transplanted islets requires several days and in-
volves angiogenesis and possibly vasculogenesis. Not only
are islets avascular for several days following transplanta-
tion, they are less vascularized and have a lower oxygen
tension than islets in the pancreas when revascularization
is complete (6,7). The death of signiﬁcant numbers of
islets in the days following transplantation results from
several factors, but ischemia and inadequate blood supply
are likely contributors to islet death in the immediate
posttransplant period and may impair islet survival and
function long term. Thus, improvements in the revascular-
ization of transplanted islets may enhance islet survival
and the outcomes of islet transplantation.
Efforts to improve the revascularization of transplanted
islets are hindered because the responsible ligands, recep-
tors, cells, and mechanisms are not well deﬁned. Recent
evidence indicates that the endothelial cells creating new
capillaries or vessels within the islet graft arise from three
sources (Fig. 1). The ﬁrst source is the endothelial cells
from the transplant recipient, which are recruited into the
islet graft. A second source is intraislet endothelial cells,
which exist in large numbers in isolated islets and may
account for up to 40% of the endothelial cells lining
capillaries within a revascularized graft (8,9). Interest-
ingly, functional vessels within a revascularized graft are
often chimeric, consisting of both endothelial cells from
the transplant recipient and donor-derived, intraislet en-
dothelial cells. Bone marrow–derived cells are a third, but
likely minor, source of endothelial cells (10,11). The
factors produced by transplanted islet cells that stimulate
or recruit endothelial cells from the three potential
sources in the graft include VEGF-A (2), but other pro- or
antiangiogenic molecules could also play a role (Fig. 1).
The formation of new vessels also requires vascular re-
modeling involving the basement membrane, vascular
supporting cells such as pericytes, and the extracellular
matrix. Little is known about these processes in islet
revascularization.
The revascularization of transplanted islets might be
enhanced or accelerated by several types of interventions.
One approach would be to increase the action of proan-
giogenic factors or to inhibit antiangiogenic factors and
thus stimulate the proliferation, migration, and maturation
of endothelial cells into functional vessels. This approach
has had some hints of success (12–15), but it is likely that
the optimal formation of mature, fully functional islet
vasculature will require precise control of the timing, dose,
and duration of angiogenic factor action in the posttrans-
plant period. A second approach could directly target
endothelial cells or enhance their ability to form mature,
functional vessels and might involve the addition of pre-
activated endothelial cells or some type of endothelial
progenitor cell population. These two approaches should
be applicable to isolated islets before transplantation or,
also, could be used to prepare the transplantation site
before transplantation of isolated islets.
In this issue of Diabetes, Johansson et al. (16) propose a
new approach using tissue engineering to enhance islet
revascularization. These investigators provide evidence
that the coculture of mesenchymal stem cells (MSCs) and
endothelial cells with human islets in vitro before trans-
plantation initiates formation of vessel-like structures that
may promote islet engraftment after transplantation.
MSCs, multipotent cells usually isolated from bone mar-
row but also present in other tissues, exhibit a wide range
of properties in other settings, properties that might
enhance islet survival (17–19). For example, MSCs posi-
tively modulate inﬂammation, tissue regeneration, and
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DIABETES, VOL. 57, SEPTEMBER 2008 2269immune attack either through cell-to-cell contact, differ-
entiation into other cell types, or by the local production
of factors such as platelet-derived growth factor. Johans-
son et al. puriﬁed MSCs from normal human bone marrow
using cell-surface markers and found that MSCs or factors
produced by these cells promoted endothelial cell prolif-
eration and migration and the “coating” of cultured islets
with endothelial cells (16). Using an in vitro system to
study angiogenesis, these investigators demonstrated that
this mixture of MSCs, endothelial cells, and islets pro-
moted the migration of exogenous endothelial cells into
the cultured islets; the formation of chimeric, vessel-like
structures between the endogenous intra-islet endothelial
cells and the endothelial cells added to the islet culture;
and the formation of new vessel “sprouts” from islets. A
unique and possibly critical component in these studies
was the microvascular endothelial cells harvested from
human dermis, which are likely more receptive to remodel-
ing signals from the MSCs. Such MSCs and microvascular
endothelial cells could likely be harvested and expanded
from the bone marrow or adipose tissue of humans selected
to receive an islet transplant.
So, how did MSCs promote these changes in endothelial
cells and promote the formation of new intraislet vascular-
like structures, and how might this be translated to islet
transplantation? Additional work is needed to deﬁne the
ligands, receptors, and mechanisms responsible for these
effects, but Johansson et al. speculate that proteases from
MSCs may degrade the islet extracellular matrix and thus
allow the migration of endothelial cells that have been
stimulated by growth factors such as VEGF-A produced by
MSCs. Identiﬁcation of these factors should allow one to
test whether addition of these factors to cultured islets
could substitute for the MSCs. As one considers how to
extend these in vitro ﬁndings, demonstration that this
coculture approach improves the function and survival of
transplanted islets using in vivo models is the critical next
step. Likewise, the long-term fate and growth potential of
MSCs must be determined and may be dependent on the
transplantation site microenviroment. Hopefully, as we
better understand the molecular events of islet revascular-
ization, delivery of angiogenic factors at the optimal dose,
time, and duration combined with tissue engineering ap-
proaches such as that described by Johansson et al. will
accelerate and enhance the revascularization of trans-
planted islets and lead to improved islet function and
survival.
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FIG. 1. Model of islet revascularization after transplantation. Endothelial cells from three sources (recipient endothelial cells at the site of
transplant, intra-islet endothelial cells, and endothelial progenitor cells from the bone marrow) contribute to revascularization. The dotted line
refers to processes or factors not yet deﬁned.
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